Obesity and Cardiovascular Disease – Redefine 3

Cardiovascular disease (CVD) is the leading cause of mortality and morbidity; globally, 121.5 million people suffered from CVD in 2016 and the incidence increased with age in both men and women. The burden of CVD is significant for patients as well as society. CVDs are the number one cause of death globally. An estimated 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. CVD is expected to account for >22.2 million deaths in 2030. Despite efforts to improve acute treatment, as well as both primary and secondary prevention which has resulted in better outcomes, many of the underlying risk factors and underlying conditions are increasing. Cardiovascular risk factors include hypertension and hyperlipidemia, but also diseases such as obesity, type 2 diabetes (T2D) and renal impairment, where the two latter diseases even have specific prevention goals in the guidelines on CVD prevention.

We are doing this study to see if CagriSema, a new medicine intended for the treatment of obesity, is safe for use in people living with obesity and cardiovascular disease. The study will also include people with type 2 diabetes and/or chronic kidney disease.

You may qualify if:

• You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral arterial disease)
• You are 55 years of age or older
• You are overweight or obese
• You have Type 2 Diabetes and/or chronic kidney disease

Qualified participants will:

• See a physician at no cost
• Receive medication that may help with weight loss
• Routine meetings with a Registered Dietician

Receive compensation for time and travel